Serum and bronchial aspiration fluid HE-4 levels in lung cancer.

Tumour Biol 2014 Sep 31;35(9):8795-9. Epub 2014 May 31.

Department of Pulmonary Diseases, School of Medicine, Ataturk University, 25240, Erzurum, Turkey,

Human epididymis 4 (HE-4) protein has been proposed as a tumor marker for lung and ovarian cancer. This study was designed to measure HE-4 levels in bronchial aspiration fluid (BAF) of patients with lung cancer and to describe the relationship of BAF HE-4 with known systemic increase in serum HE-4 levels. Sixty-four patients with lung cancer, 38 with benign lung disease and 19 healthy subjects, were enrolled in our study. The BAF was obtained during routine bronchoscopic procedure in patient groups. HE-4 levels in serum and BAF were measured with the commercially available kit by an enzyme-linked immunosorbent assay. Serum HE-4 levels were significantly higher in patients with lung cancer group (204.2 ± 22.9 pmol/L) than in benign lung disease group (135 ± 26.9 pmol/L, p = 0.001) and healthy subjects (14.8 ± 7.0 pmol/L, p < 0.0001). No significant difference was observed in terms of BAF HE-4 values in two patient groups. BAF HE-4 levels were significantly higher than those of serum levels in both patient groups (p < 0.0001). Serum HE-4 level was correlated with tumor stage (p = 0.001) and age (p < 0.0001) in the lung cancer group. The areas under the receiver operating characteristic (ROC) curve of serum HE-4 was 0.784 (95 % confidence interval (CI), 0.701-0.867) and that of BAF HE-4 was 0.496 (95 % CI, 0.382-0.610). This study shows that a systemic increase in serum of HE-4 is more prominent than a local increase of HE-4 (BAF), so this may suggest the feasibility of using serum instead of BAF samples for HE-4 measurements in lung cancer cases.

Download full-text PDF

Source
http://link.springer.com/content/pdf/10.1007/s13277-014-2134
Web Search
http://link.springer.com/10.1007/s13277-014-2134-3
Publisher Site
http://dx.doi.org/10.1007/s13277-014-2134-3DOI Listing
September 2014

Similar Publications

[The values of serum human epididymis secretory protein 4 and CA(125) assay in the diagnosis of ovarian malignancy].

Zhonghua Fu Chan Ke Za Zhi 2008 Dec;43(12):931-6

Gynecologic Oncology Center, Peking University People's Hospital, Beijing 100044, China.

Objective: To evaluate the value of human epididymis secretory protein 4 (HE4) and CA(125) in the diagnosis of ovarian malignancy.

Methods: HE4 and CA(125) in the serum specimens of malignant ovarian tumor group (30 cases), benign ovarian diseases (110 cases; 45 benign ovarian tumor, 57 endometriotic diseases and 8 pelvic inflammation were included) and healthy women group (137 cases) were assayed double blindly. The levels and the diagnosis efficiency of the HE4 and CA(125) were analyzed. Read More

View Article and Full-Text PDF
December 2008

Serum human epididymis protein 4 (HE4) as a tumor marker in men with lung cancer.

Clin Chem Lab Med 2014 Nov;52(11):1639-48

Background: Human epididymis protein 4 (HE4) is a reliable tumor marker for ovarian cancer, but only limited data are available on HE4 levels in lung malignancies.

Methods: HE4 levels were measured at diagnosis in 98 men with lung cancer at different stages of the disease, and these results were compared to an age-matched healthy male cohort (n=98). The concentrations of classical tumor markers were also determined, and their efficacy was compared to that of HE4. Read More

View Article and Full-Text PDF
November 2014

Evaluating the clinical significance of serum HE4 levels in lung cancer and pulmonary tuberculosis.

Int J Tuberc Lung Dis 2013 Oct;17(10):1346-53

State Key Laboratory of Oncology in Southern China, and Department of Clinical Laboratory Medicine, Sun Yat-Sen University Cancer Centre, Guangzhou, China.

Objective: To evaluate whether serum human epididymis protein 4 (HE4) levels could be used as a marker to differentiate lung cancer from pulmonary tuberculosis (PTB) and as a prognostic indicator in patients with non-small-cell lung cancer (NSCLC).

Design: HE4 levels were measured in serum samples from 106 healthy controls, 190 lung cancer patients, 114 patients with PTB and 24 patients with pneumonia using enzyme-linked immunosorbent assay.

Results: Serum HE4 levels in lung cancer patients were significantly higher than those in patients with PTB and healthy controls (P < 0. Read More

View Article and Full-Text PDF
October 2013

Serum reactive oxygen species modulator 1 (Romo1) as a potential diagnostic biomarker for non-small cell lung cancer.

Lung Cancer 2014 Aug 5;85(2):175-81. Epub 2014 Jun 5.

Division of Respiratory and Critical Care Medicine, Department of Internal Medicine, College of Medicine, Korea University, Seoul, Republic of Korea. Electronic address:

Objectives: Reactive oxygen species modulator 1 (Romo1) is a novel protein that localizes in the mitochondrial membrane and induces mitochondrial reactive oxygen species (ROS) generation. Romo1 is increased in most cancer cell lines and is related with resistance to chemotherapy in vitro. However, data on its expression in patients with malignancy is very limited. Read More

View Article and Full-Text PDF
August 2014